Fully enclosed, fully automated, and ready-to-use! Zhuowei Technology releases new product CytoNexus, a flow sample pre-processing instrument

In late December 2025, Jiangsu Zhuowei Microbiology Technology Co., Ltd. officially launched CytoNexus, an innovative fully enclosed, fully automated, and ready-to-use intelligent system for flow cytometry sample pretreatment. This product, with its three core breakthroughs of fully enclosed operation, automated process, and plug-and-play design, directly addresses industry pain points. It brings standardized and efficient sample pretreatment solutions to fields such as clinical testing, scientific research, and biopharmaceuticals, garnering industry attention.

▉ Addressing industry pain points and filling market gaps The sample pre-processing step in current flow cytometry analysis has long faced multiple challenges: manual operation requires 30-60 minutes per sample, with high pressure for batch processing and high labor costs; manual operation differences often lead to CV values exceeding 15%, resulting in poor data comparability; open operation is prone to generating aerosols, posing risks of cross-contamination and occupational exposure. Even existing automated equipment faces issues such as high price, complex operation, low purification efficiency, and limited sample adaptability. The launch of CytoNexus precisely addresses these pain points. Positioned as "fully enclosed, fully automated, and ready-to-use," it is specifically designed for flow cytometry analysis, capable of automatically completing the entire process of lysis, washing, staining, and enrichment. It supports common clinical samples such as whole blood, bone marrow, and PBMC, with a maximum processing speed of just 5 minutes per sample. This has completely changed the inefficient and high-cost traditional pre-processing mode, and provides higher standardized operation, helping to efficiently expand the application of flow cytometry.

▉ Three core innovations redefine the technological benchmark. CytoNexus's core strengths are embodied in three innovative highlights, which have built a competitive barrier of differentiation: 1. Fully automated processing, unleashing human potential: After one-click start, it can operate unattended, without the need for technical personnel intervention throughout the process. This frees laboratory personnel from tedious and repetitive operations, significantly enhancing batch sample processing capabilities, especially for handling tasks during peak periods. 2. Closed microfluidic chip, establishing a robust safety barrier: It adopts a zero-opening, fully gas-path operation design, with no direct liquid interaction between the chip and the equipment. This fundamentally eliminates the risk of cross-contamination and avoids occupational exposure caused by aerosols, significantly enhancing biosafety levels. 3. Self-configuring dyes and antibodies, plug-and-play design, lowering the barrier to use: The chip comes pre-loaded with reagents, and capsule-type antibody dyes are pre-encapsulated, eliminating the need for users to manually prepare solutions. This not only simplifies the operation process but also effectively reduces human errors, ensuring the stability and reliability of experimental results. Coupled with disposable chips, it avoids cross-contamination and further ensures data accuracy. In terms of technical support, CytoNexus achieves precise flow control of liquids in microchannels through a built-in pump and valve system and an original one-way valve structure; innovative centrifuge-free purification technology and magnetic/gravity-controlled ball valve structure enable efficient purification without the need for centrifuge equipment, avoiding the impact of the centrifugation process on cell viability.

▉ Widely adaptable across multiple scenarios, empowering industry development. CytoNexus, with its excellent performance, has demonstrated application value in multiple fields: 1. Clinical laboratory: It shortens the reporting cycle of emergency flow cytometry to within 1 hour, significantly enhancing the timeliness of emergency diagnosis and buying precious time for patient treatment; 2. Research laboratories: Standardized processing procedures ensure data consistency in multi-center immunological research, facilitating the publication of high-level academic achievements; 3. CAR-T/CRO institutions: It achieves GMP-level pre-processing standardization, meeting compliance audit requirements and ensuring the safety and quality of biopharmaceutical research and production; 4. Centers for Disease Control and Public Health institutions: It supports sample screening during outbreaks, quickly responding to public health emergency needs. Furthermore, the product strives for excellence in user experience: with a minimalist operation of three steps (adding samples, adding reagent capsules, inserting the chip and pressing start), coupled with a Chinese touch screen, new employees can operate independently within 30 minutes; the electronic logs generated during each run support data traceability and user management, meeting quality control and audit requirements, truly achieving "as simple as using a coffee machine, yet producing high-quality scientific research data.".

As a revolutionary product in the field of flow cytometry sample pre-processing, CytoNexus not only addresses the long-standing challenges of efficiency, safety, and standardization in the industry, but also drives the development of flow analysis towards greater precision, efficiency, and convenience through technological innovation. Jiangsu Zhuowe Microbiology Technology Co., Ltd. will take CytoNexus as a starting point, continue to delve into the field of intelligent sample processing quality control, and inject new vitality into the life science research and clinical testing industries.